therapeutic control of the immune system l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Therapeutic Control of the Immune System PowerPoint Presentation
Download Presentation
Therapeutic Control of the Immune System

Loading in 2 Seconds...

play fullscreen
1 / 17

Therapeutic Control of the Immune System - PowerPoint PPT Presentation


  • 118 Views
  • Uploaded on

Therapeutic Control of the Immune System. June, 2004. Corporate Profile & Mission. Private R&D focused Immunology company with proprietary product candidates addressing large markets with unmet needs

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Therapeutic Control of the Immune System' - feo


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
corporate profile mission
Corporate Profile & Mission
  • Private R&D focused Immunology company with proprietary product candidates addressing large markets with unmet needs
  • Targeting regulatory pathways to restore balance to the immune system in conditions associated with abnormal and harmful immune responses
history
History

Robart’s Research Institute

1996

University Health

Network

St. Michael’s Hospital

U. of Toronto

U. of Western Ontario

London Health Sciences Centre

trillium today
Trillium Today
  • Operating in ~10,000 sq. ft. fully equipped R&D facility in Toronto
  • Staff: 13
  • 4 R&D Programs
  • Recently closed $13.5M Series A Financing
corporate strengths
Corporate Strengths
  • Strong and innovative science
  • Proof-of-principle in vivo data
  • Multiple product opportunities in large markets
  • World class academic and industry R&D collaborators
  • Comprehensive patent portfolio
  • Experienced and committed leadership
proven business model
Proven Business Model

Research

R&D Interface

Development

Scale-up/Formulation

PK/Metabolism

Toxicology

Phase I/Phase IIa

Target ID

Target Characterization

Target Validation

Lead ID

Lead Optimization

Commercial Process

Commercial Formulation

Phase IIb/Phase III

Worldwide registration

Lead Compound

Development Candidate

Marketed Drug

three lead programs four product opportunities
Three Lead Programs - Four Product Opportunities
  • CD200

CD200Fc: (Primary indications: autoimmunity & transplantation)

CD200 MAb: (Primary indications: hematological malignancies)

  • Pro-inflammatory cytokines

Receptor antagonists (Primary indications: Inflammatory disease & cancer)

  • Fgl2

Fgl2 MAb: (Primary indication: viral hepatitis)

a solid research foundation
A Solid Research Foundation
  • Sponsored Research Agreements
    • Dr. R Gorczynski: CD200 (University Health Network, Toronto)
    • Dr. G. Levy: Fgl2 (University Health Network, Toronto)
    • Dr. S. Chemtob: Cytokine R (St. Justine Hospital, Montreal)
  • Academic Research Collaborators in:
    • Baltimore
    • Berlin
    • Boston
    • Bristol
    • Calgary
    • London (UK)
    • Maastricht
    • San Diego
    • San Francisco
    • Tübingen
market opportunity 20 billion
Market Opportunity > $20 Billion
  • Diabetes
  • Rheumatoid Arthritis
  • Psoriasis
  • Inflammatory Bowel Disease
  • Multiple Sclerosis
  • Acute Graft Rejection
  • Myocarditis
  • HIV
  • Viral Hepatitis
  • Cancer
  • Nephritis
  • Allergies
  • Lupus
  • Eczema/Dermatitis
clear patent strategy
Clear Patent Strategy

Major market coverage (US, EP, JP, CA, AU)

management team
Management Team
  • Niclas Stiernholm, Ph.D. Chief Executive Officer

(Allelix, YM Biosciences)

  • Bob Uger, Ph.D. Vice President, R&D

(Aventis Pasteur)

  • Scott Duncan, B.Sc. Director, Patents & Licensing

(Allelix)

  • James Parsons, CA Director, Finance & Admin.

(Lorus Therapeutics)

board of directors
Calvin Stiller, MD (Chair)

Chairman, Ontario Research and Development Fund & Canadian Medical Discoveries Fund

Brian Underdown, Ph.D.

Managing Director, Science and Technology, MDS Capital Corp.

Niclas Stiernholm, Ph.D.

TTI CEO

Robert Hall, M.B.A.

Director, Venture Capital Division, Business Development Bank of Canada

Julia Levy, Ph.D.

Founder and Executive Chairman, Scientific Advisory Board, QLT Inc.

Elizabeth Corsi, Pharm D.President & Chief Executive Officer, Eximias Pharmaceutical Corporation

Michael Moore, Ph.D. D.Sc.

Chief Executive Officer, PIramed Ltd.

Gary Levy, M.D.

TTI Founding Scientist Representative

Board of Directors
scientific advisory board
Scientific Advisory Board
  • G. Levy, M.D. (Chair)

Director, Multi-Organ Transplant Program at The Toronto Hospital and CIHR Group in Immunology and Transplantation

  • M. Sayegh, M.D.

Director of Research, Immunogenetics and Transplantation, Brigham and Women’s Hospital, Boston

  • B. Barber, Ph.D.

Executive Vice President, University Health Network Global Ventures

  • V. Kuchroo, DVM, Ph.D.

Associate Professor of Neurology, Harvard Medical School, Boston

  • M. Feldmann, M.D., Ph.D.

Professor, Head Kennedy Institute of Rheumatology, Imperial College London, UK

capitalization
Capitalization
  • $4.8 M Novartis Inc. contract research (1996-2001)
  • $250 K Seed financing (1998)
  • $180 K IRAP (2002)
  • $13.5 M Series A financing (2004)
defined path forward
Defined Path Forward
  • Near Term (24 mo):
    • Secure CD200 partnership(s)
    • Expand product portfolio; In-house R&D/In-licensing
    • CD200Fc IND/CTA
  • Long Term (Yr 3-5):
    • Phase II/III trials (partner)
    • Additional IND/CTA filings
    • Financing
    • Exit
corporate strengths16
Corporate Strengths
  • Strong and innovative science
  • Proof-of-principle in vivo data
  • Multiple product opportunities in large markets
  • World class academic and industry R&D collaborators
  • Comprehensive patent portfolio
  • Experienced and committed leadership
contacts
Contacts

Niclas Stiernholm, PhD

Chief Executive Officer

Tel: 416-595-0627 x222

niclas@trilliumtherapeutics.com

96 Skyway Avenue

Toronto, Ontario, M9W 4Y9

CANADA

Bob Uger, PhD

Vice President, R&D

Tel: 416-595-0627 x260

bob@trilliumtherapeutics.com